The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

被引：336

作者：

Athauda, Dilan ^{[1
]}

Foltynie, Thomas

机构：

[1] UCL Inst Neurol, Sobell Dept Motor Neurosci, Queen Sq, London WC1N 3BG, England

来源：

DRUG DISCOVERY TODAY | 2016年 / 21卷 / 05期

关键词：

NF-KAPPA-B; AMYLOID-BETA PEPTIDE; INSULIN-DEGRADING ENZYME; PROGENITOR-CELL PROLIFERATION; PROTECTS HIPPOCAMPAL-NEURONS; ALPHA-SYNUCLEIN AGGREGATION; LIRAGLUTIDE IMPROVES MEMORY; GLYCOGEN-SYNTHASE KINASE-3; INCRETIN-BASED THERAPIES; LONG-TERM POTENTIATION;

D O I：

10.1016/j.drudis.2016.01.013

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Growing evidence suggests that agonists of the glucagon-like peptide 1 (GLP-1) receptor provide neuroprotection across a range of experimental models of Parkinson's disease (PD) and, recently, a small proof-of-concept, open-label human trial of exenatide in the treatment moderate severity PD appeared to show persistent improvements in motor and cognitive function. The underlying mechanisms of action remain unclear, but as evidence for the potential use of GLP-1 agonists in treating several neurodegenerative disease mounts, and with several clinical trials of GLP-1 analogues in PD and Alzheimer's disease (AD) currently underway, here we review the molecular mechanisms underlying the neuroprotective effects of GLP-1 analogues in the laboratory and their potential therapeutic utility with particular relevance to PD and PD dementia (PDD).

引用

页码：802 / 818

页数：17

共 253 条

[1]

Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease [J].

Abbas, Talib ;

Faivre, Emilie ;

Hoelscher, Christian .

BEHAVIOURAL BRAIN RESEARCH, 2009, 205 (01) :265-271

[2]

Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease [J].

Abbott, Sarah K. ;

Li, Hongyun ;

Munoz, Sonia Sanz ;

Knoch, Bianca ;

Batterham, Marijka ;

Murphy, Karen E. ;

Halliday, Glenda M. ;

Garner, Brett .

MOVEMENT DISORDERS, 2014, 29 (04) :518-526

[3]

Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2 antioxidant signaling pathways [J].

Abdelsalam, Rania M. ;

Safar, Marwa M. .

JOURNAL OF NEUROCHEMISTRY, 2015, 133 (05) :700-707

[4]

Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study [J].

Ahern, T. ;

Tobin, A. -M. ;

Corrigan, M. ;

Hogan, A. ;

Sweeney, C. ;

Kirby, B. ;

O'Shea, D. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (11) :1440-1443

[5]

The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem [J].

Alvarez, E ;

Martínez, MD ;

Roncero, I ;

Chowen, JA ;

García-Cuartero, B ;

Gispert, JD ;

Sanz, C ;

Vázquez, P ;

Maldonado, A ;

de Cáceres, J ;

Desco, M ;

Pozo, MA ;

Blázquez, E .

JOURNAL OF NEUROCHEMISTRY, 2005, 92 (04) :798-806

[6]

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4 [J].

Arakawa, Masayuki ;

Mita, Tomoya ;

Azuma, Kosuke ;

Ebato, Chie ;

Goto, Hiromasa ;

Nomiyama, Takashi ;

Fujitani, Yoshio ;

Hirose, Takahisa ;

Kawamori, Ryuzo ;

Watada, Hirotaka .

DIABETES, 2010, 59 (04) :1030-1037

[7]

Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson's Disease [J].

Aviles-Olmos, Iciar ;

Dickson, John ;

Kefalopoulou, Zinovia ;

Djamshidian, Atbin ;

Kahan, Joshua ;

Ell, Peter ;

Whitton, Peter ;

Wyse, Richard ;

Isaacs, Tom ;

Lees, Andrew ;

Limousin, Patricia ;

Foltynie, Thomas .

JOURNAL OF PARKINSONS DISEASE, 2014, 4 (03) :337-344

[8]

Exenatide and the treatment of patients with Parkinson's disease [J].

Aviles-Olmos, Iciar ;

Dickson, John ;

Kefalopoulou, Zinovia ;

Djamshidian, Atbin ;

Ell, Peter ;

Soderlund, Therese ;

Whitton, Peter ;

Wyse, Richard ;

Isaacs, Tom ;

Lees, Andrew ;

Limousin, Patricia ;

Foltynie, Thomas .

JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (06) :2730-2736

[9]

Biology of incretins: GLP-1 and GIP [J].

Baggio, Laurie L. ;

Drucker, Daniel J. .

GASTROENTEROLOGY, 2007, 132 (06) :2131-2157

[10]

[11C]-PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? [J].

Bartels, A. L. ;

Willemsen, A. T. M. ;

Doorduin, J. ;

de Vries, E. F. J. ;

Dierckx, R. A. ;

Leenders, K. L. .

PARKINSONISM & RELATED DISORDERS, 2010, 16 (01) :57-59

← 1 2 3 4 5 6 7 8 9 10 →